Tiziana Rancati

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6151866/publications.pdf

Version: 2024-02-01

181	4,644	87888 38	110387 64
papers	citations	h-index	g-index

185	185	185	4867
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Design, construction and tests of the ICARUS T600 detector. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2004, 527, 329-410.	1.6	362
2	Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiotherapy and Oncology, 2003, 67, 275-283.	0.6	253
3	Doseâ€“volume effects for normal tissues in external radiotherapy: Pelvis. Radiotherapy and Oncology, 2009, 93, 153-167.	0.6	249
4	Radiation Doseâ€“Volume Effects in the Larynx and Pharynx. International Journal of Radiation Oncology Biology Physics, 2010, 76, S64-S69.	0.8	189
5	Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiotherapy and Oncology, 2004, 73, 21-32.	0.6	183
6	Clinical and Dosimetric Predictors of Late Rectal Syndrome After 3D-CRT for Localized Prostate Cancer: Preliminary Results of a Multicenter Prospective Study. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1130-1137.	0.8	132
7	A 3-dimensional calculation of the atmospheric neutrino fluxes. Astroparticle Physics, 2000, 12, 315-333.	4.3	107
8	Predictors for Rectal and Intestinal Acute Toxicities During Prostate Cancer High-Dose 3D-CRT: Results of a Prospective Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1401-1410.	0.8	91
9	Study of electron recombination in liquid argon with the ICARUS TPC. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2004, 523, 275-286.	1.6	87
10	The Extended Range Neutron Rem Counter LINUS: Overview and Latest Developments. Radiation Protection Dosimetry, 1998, 76, 135-148.	0.8	82
11	T2wâ€MRI signal normalization affects radiomics features reproducibility. Medical Physics, 2020, 47, 1680-1691.	3.0	82
12	Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. European Urology, 2013, 64, 30-36.	1.9	81
13	miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. Cancer Letters, 2017, 395, 53-62.	7.2	80
14	Predicting toxicity in radiotherapy for prostate cancer. Physica Medica, 2016, 32, 521-532.	0.7	75
15	Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: Results of a large multicenter observational study. Radiotherapy and Oncology, 2009, 93, 197-202.	0.6	71
16	Development of a Set of Nomograms to Predict Acute Lower Gastrointestinal Toxicity for Prostate Cancer 3D-CRT. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1065-1073.	0.8	68
17	Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. Radiotherapy and Oncology, 2011, 100, 124-130.	0.6	65
18	Semantics in active surveillance for men with localized prostate cancer â€" results of a modified Delphi consensus procedure. Nature Reviews Urology, 2017, 14, 312-322.	3.8	65

#	Article	IF	Citations
19	miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCÎµ and ZEB1 inhibition. Journal of Experimental and Clinical Cancer Research, 2019, 38, 51.	8.6	64
20	Scintillation efficiency of nuclear recoil in liquid xenon. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2000, 449, 147-157.	1.6	63
21	Calculation of the Radiation Environment Caused by Galactic Cosmic Rays for Determining Air Crew Exposure. Radiation Protection Dosimetry, 2001, 93, 101-114.	0.8	60
22	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	1.9	58
23	Analysis of the liquid argon purity in the ICARUS T600 TPC. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2004, 516, 68-79.	1.6	55
24	To Bleed or Not to Bleed. A Prediction Based on Individual Gene Profiling Combined With Doseâ€“Volume Histogram Shapes in Prostate Cancer Patients Undergoing Three-Dimensional Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1431-1440.	0.8	55
25	Machine Learning and Radiogenomics: Lessons Learned and Future Directions. Frontiers in Oncology, 2018, 8, 228.	2.8	54
26	Early clinical and radiological pulmonary complications following breast cancer radiation therapy: NTCP fit with four different models. Radiotherapy and Oncology, 2007, 82, 308-316.	0.6	53
27	REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 2019, 138, 59-67.	0.6	53
28	The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International, 2018, 121, 737-744.	2.5	51
29	Measurement of the Î¼ decay spectrum with the ICARUS liquid Argon TPC. European Physical Journal C, 2004, 33, 233-241.	3.9	50
30	The 6â€year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU International, 2012, 110, 998-1003.	2.5	47
31	First application of a pixel-wise analysis on bladder doseâ€“surface maps in prostate cancer radiotherapy. Radiotherapy and Oncology, 2016, 119, 123-128.	0.6	47
32	Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model. Physics in Medicine and Biology, 2012, 57, 1399-1412.	3.0	44
33	Relationships between bladder doseâ€“volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer. Radiotherapy and Oncology, 2014, 111, 100-105.	0.6	43
34	Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. Oral Oncology, 2019, 99, 104453.	1.5	43
35	NTCP Modeling of Subacute/Late Laryngeal Edema Scored by Fiberoptic Examination. International Journal of Radiation Oncology Biology Physics, 2009, 75, 915-923.	0.8	42
36	Feasibility of safe ultra-high (EQD₂>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotheraphy. Acta OncolÃ³gica, 2011, 50, 25-34.	1.8	42

#	Article	IF	Citations
37	Is It Time to Tailor the Prediction of Radio-Induced Toxicity in Prostate Cancer Patients? Building the First Set of Nomograms for Late Rectal Syndrome. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1957-1966.	0.8	41
38	Contouring Variability of the Penile Bulb on CT Images: Quantitative Assessment Using a Generalized Concordance Index. International Journal of Radiation Oncology Biology Physics, 2012, 84, 841-846.	0.8	41
39	miRNAs in tumor radiation response: bystanders or participants?. Trends in Molecular Medicine, 2014, 20, 529-539.	6.7	40
40	Predictive models of toxicity in external radiotherapy. Cancer, 2009, 115, 3135-3140.	4.1	39
41	Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: The case of previous abdominal surgery. Results from a prospective trial. Radiotherapy and Oncology, 2012, 103, 252-255.	0.6	39
42	Performance of a liquid argon time projection chamber exposed to the CERN West Area Neutrino Facility neutrino beam. Physical Review D, 2006, 74, .	4.7	38
43	Late Fecal Incontinence After High-Dose Radiotherapy for Prostate Cancer: Better Prediction Using Longitudinal Definitions. International Journal of Radiation Oncology Biology Physics, 2012, 83, 38-45.	0.8	38
44	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Frontiers in Oncology, 2017, 7, 83.	2.8	36
45	Embracing Phenomenological Approaches to Normal Tissue Complication Probability Modeling: A Question of Method. International Journal of Radiation Oncology Biology Physics, 2015, 91, 468-471.	0.8	34
46	Predictive models of toxicity with external radiotherapy for prostate cancer. Cancer, 2009, 115, 3141-3149.	4.1	33
47	Bladder spatial-dose descriptors correlate with acute urinary toxicity after radiation therapy for prostate cancer. Physica Medica, 2016, 32, 1681-1689.	0.7	31
48	Long term rectal function after high-dose prostatecancer radiotherapy: Results from a prospective cohort study. Radiotherapy and Oncology, 2014, 110, 272-277.	0.6	30
49	Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials. Critical Reviews in Oncology/Hematology, 2016, 108, 13-22.	4.4	30
50	Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients. Clinical Oncology, 2019, 31, 9-16.	1.4	30
51	Daily Sodium Butyrate Enema for the Prevention of Radiation Proctitis in Prostate Cancer Patients Undergoing Radical Radiation Therapy: Results of a Multicenter Randomized Placebo-Controlled Dose-Finding Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 518-524.	0.8	29
52	Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: Results of a cohort study. Radiotherapy and Oncology, 2015, 116, 185-191.	0.6	29
53	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. Cancers, 2020, 12, 2958.	3.7	29
54	Modelling the Impact of Fractionation on Late Urinary Toxicity After Postprostatectomy Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1250-1257.	0.8	27

#	Article	IF	Citations
55	Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel doseâ€“volume effects. Radiotherapy and Oncology, 2017, 124, 296-301.	0.6	26
56	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. Oral Oncology, 2018, 86, 266-272.	1.5	26
57	Observation of long ionizing tracks with the ICARUS T600 first half-module. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2003, 508, 287-294.	1.6	25
58	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	5.4	24
59	Detection of Cherenkov light emission in liquid argon. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2004, 516, 348-363.	1.6	23
60	Bladder doseâ€“surface maps and urinary toxicity: Robustness with respect to motion in assessing local dose effects. Physica Medica, 2016, 32, 506-511.	0.7	22
61	Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. Radiotherapy and Oncology, 2016, 118, 92-98.	0.6	22
62	Performance of the ICARUS liquid argon prototype. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2003, 498, 292-311.	1.6	21
63	Patient-reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the doseâ€“effect. Radiotherapy and Oncology, 2017, 125, 101-106.	0.6	21
64	A Multicentre Evaluation of Dosiomics Features Reproducibility, Stability and Sensitivity. Cancers, 2021, 13, 3835.	3.7	21
65	Understanding Urinary Toxicity after Radiotherapy for Prostate Cancer: First Steps Forward. Tumori, 2017, 103, 395-404.	1.1	20
66	Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?. Tumori, 2017, 103, 464-474.	1.1	20
67	Correlation between surrogates of bladder dosimetry and doseâ€“volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy. Radiotherapy and Oncology, 2012, 105, 180-183.	0.6	18
68	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	1.9	18
69	ICARUS: an innovative detector for underground physics. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2001, 461, 324-326.	1.6	17
70	Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning. Radiation Oncology, 2011, 6, 123.	2.7	17
71	Local dose analysis to predict acute and late urinary toxicities after prostate cancer radiotherapy: Assessment of cohort and method effects. Radiotherapy and Oncology, 2020, 147, 40-49.	0.6	17
72	Breast cancer patient perspective on opportunities and challenges of a genetic test aimed to predict radio-induced side effects before treatment: Analysis of the Italian branch of the REQUITE project. Radiologia Medica, 2021, 126, 1366-1373.	7.7	17

#	Article	IF	Citations
73	The Role of the Quantities used in Radiological Protection for the Assessment of the Exposure to Cosmic Radiation. Radiation Protection Dosimetry, 1999, 83, 199-210.	0.8	15
74	Patterns in ano-rectal dose maps and the risk of late toxicity after prostate IMRT. Acta OncolÃ³gica, 2019, 58, 1757-1764.	1.8	15
75	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. Frontiers in Oncology, 2020, 10, 541281.	2.8	15
76	Development of a Ready-to-Use Graphical Tool Based on Artificial Neural Network Classification: Application for the Prediction of Late Fecal Incontinence After Prostate Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1533-1542.	0.8	14
77	Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate Cancer: New Insights From External Independent Validation. International Journal of Radiation Oncology Biology Physics, 2018, 102, 127-136.	0.8	14
78	Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations. Physics in Medicine and Biology, 2021, 66, 12TR01.	3.0	14
79	Long-term biochemical control of prostate cancer after standard or hyper-fractionation: Evidence for different outcomes between lowâ€“intermediate and high risk patients. Radiotherapy and Oncology, 2011, 101, 454-459.	0.6	13
80	Reducing rectal injury during external beam radiotherapy for prostate cancer. Nature Reviews Urology, 2013, 10, 345-357.	3.8	13
81	Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy. Disease Markers, 2018, 2018, 1-9.	1.3	13
82	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.4	13
83	Impact of the radiotherapy technique on the correlation between doseâ€“volume histograms of the bladder wall defined on MRI imaging and doseâ€“volume/surface histograms in prostate cancer patients. Physics in Medicine and Biology, 2013, 58, N115-N123.	3.0	12
84	Modelling late stool frequency and rectal pain after radical radiotherapy in prostate cancer patients: Results from a large pooled population. Physica Medica, 2016, 32, 1690-1697.	0.7	12
85	Modelling Radiotherapy Side Effects. , 0, , .		12
86	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. European Urology, 2017, 71, 274-280.	1.9	11
87	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Radiotherapy and Oncology, 2021, 159, 241-248.	0.6	11
88	Baseline status and dose to the penile bulb predict impotence 1Âyear after radiotherapy for prostate cancer. Strahlentherapie Und Onkologie, 2016, 192, 297-304.	2.0	10
89	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Radiotherapy and Oncology, 2022, 168, 75-82.	0.6	10
90	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Frontiers in Oncology, 2020, 10, 575909.	2.8	10

#	Article	IF	Citations
91	First observation of 140-cm drift ionizing tracks in the ICARUS liquid-argon TPC. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2000, 449, 36-41.	1.6	9
92	The ICARUS liquid argon time projection chamber. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2001, 471, 272-275.	1.6	8
93	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	5.4	8
94	How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study. Supportive Care in Cancer, 2021, 29, 645-651.	2.2	8
95	Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables. Cancers, 2021, 13, 2433.	3.7	8
96	Proton Radiation Therapy for Nasopharyngeal Cancer Patients: Dosimetric and NTCP Evaluation Supporting Clinical Decision. Cancers, 2022, 14, 1109.	3.7	8
97	Breast irradiation with three conformal photon fields for patients with high lung involvement. Acta OncolÃ³gica, 2004, 43, 558-566.	1.8	7
98	Texture analysis of T1â€w and T2â€w MR images allows a quantitative evaluation of radiationâ€induced changes of internal obturator muscles after radiotherapy for prostate cancer. Medical Physics, 2018, 45, 1518-1528.	3.0	7
99	Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations. European Urology Oncology, 2019, 2, 277-285.	5.4	7
100	Predictors of 2-Year Incidence of Patient-Reported Urinary Incontinence After Post-prostatectomy Radiotherapy: Evidence of Dose and Fractionation Effects. Frontiers in Oncology, 2020, 10, 1207.	2.8	7
101	Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?. Frontiers in Psychology, 2020, 11, 576459.	2.1	7
102	Determination of through-going tracksâ€™ direction by means of Î´-rays in the ICARUS liquid argon time projection chamber. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2000, 449, 42-47.	1.6	6
103	â€œWhat ifâ€¦â€• Decisional Regret in Patients who Discontinued Active Surveillance. Tumori, 2016, 102, 562-568.	1.1	6
104	Towards spatial representations of dose distributions to predict risk of normal tissue morbidity after radiotherapy. Physics and Imaging in Radiation Oncology, 2020, 15, 105-107.	2.9	6
105	Radiobiological Studies of Microvascular Damage through In Vitro Models: A Methodological Perspective. Cancers, 2021, 13, 1182.	3.7	6
106	Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort. Advances in Radiation Oncology, 2022, 7, 100890.	1.2	6
107	Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance. Tumori, 2018, 104, 172-178.	1.1	5
108	Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study. Radiotherapy and Oncology, 2021, 158, 74-82.	0.6	5

#	Article	IF	Citations
109	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). Lung Cancer, 2022, 166, 228-241.	2.0	5
110	Comment on â€œObjective assessment in digital images of skin erythema caused by radiotherapyâ€•[Med. Phys. 42, 5568-5577 (2015)]. Medical Physics, 2016, 43, 2687-2688.	3.0	4
111	PV-0627: Hematologic toxicity after whole-pelvis irradiation: results of a longitudinal observational study. Radiotherapy and Oncology, 2018, 127, S332-S333.	0.6	4
112	OC-0647 Analysis of biomarkers for late radiotherapy toxicity in the REQUITE project. Radiotherapy and Oncology, 2019, 133, S343.	0.6	4
113	A global sensitivity analysis approach applied to a multiscale model of microvascular flow. Computer Methods in Biomechanics and Biomedical Engineering, 2020, 23, 1215-1224.	1.6	4
114	In silico model of the early effects of radiation therapy on the microcirculation and the surrounding tissues. Physica Medica, 2020, 73, 125-134.	0.7	4
115	Artificial intelligence applied to medicine: There is an â€œelephant in the roomâ€• Physica Medica, 2022, 98, 8-10.	0.7	4
116	Methodology and technology for the development of a prognostic MRI-based radiomic model for the outcome of head and neck cancer patients. , 2020, 2020, 1152-1155.		3
117	External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. Frontiers in Oncology, 2020, 10, 910.	2.8	3
118	Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study. Tumori, 2022, , 030089162210780.	1.1	3
119	PV-0321: Influence of urethra contouring on NTCP models predicting urethral strictures in prostate HDRB. Radiotherapy and Oncology, 2018, 127, S170.	0.6	2
120	Predictors of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after Prostatectomy: Impact of Time between Surgery and Radiotherapy. Cancers, 2021, 13, 3243.	3.7	2
121	Reply from Authors re: Laurence Klotz. Active Surveillance, Quality of Life, and Cancer-related Anxiety. Eur Urol 2013;64:37â€“9. European Urology, 2013, 64, 39-40.	1.9	1
122	Incidence of Late Severe Urinary Symptoms after Radical IMRT for Prostate Cancer: Effect of Bladder Doses and Hypofractionation. International Journal of Radiation Oncology Biology Physics, 2017, 99, S167-S168.	0.8	1
123	PO-0850: Predicting late fecal incontinence risk after RT for prostate cancer:external independent validation. Radiotherapy and Oncology, 2017, 123, S461.	0.6	1
124	PO-112 Role of microbiota in predicting oral mucositis in head and neck cancer patients treated with IMRT. Radiotherapy and Oncology, 2019, 132, 57.	0.6	1
125	In Reply to Loganadane etÂal. International Journal of Radiation Oncology Biology Physics, 2019, 103, 777-778.	0.8	1
126	Editorial: Modeling for Prediction of Radiation-Induced Toxicity to Improve Therapeutic Ratio in the Modern Radiation Therapy Era. Frontiers in Oncology, 2021, 11, 690649.	2.8	1

#	Article	IF	Citations
127	Modelling Radiation-Induced Salivary Dysfunction during IMRT and Chemotherapy for Nasopharyngeal Cancer Patients. Cancers, 2021, 13, 3983.	3.7	1
128	The scientific publications of AIFM members in 2015â€“2019: A survey of the FutuRuS working group. Physica Medica, 2021, 88, 111-116.	0.7	1
129	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Frontiers in Oncology, 2020, 10, 575909.	2.8	1
130	Genome wide association study of acute radiation toxicity and quality of life in breast cancer patients â€“ results from the REQUITE cohort study. European Journal of Cancer, 2020, 138, S12.	2.8	1
131	Study of the Dosimetric Characteristics of Cosmic Radiation at Civil Aviation Altitudes. Radiation Protection Dosimetry, 2002, 102, 305-314.	0.8	0
132	Event generators for simulating heavy ion interactions to evaluate the radiation risks in spaceflight. , 2005, , .		0
133	Editorial Comment to Healthâ€related quality of life after carbonâ€ion radiotherapy for prostate cancer: A 3â€year prospective study. International Journal of Urology, 2014, 21, 375-376.	1.0	0
134	A Higher Whole-Pelvic Integral Dose Is Associated With Worsening Fatigue and Functional Outcome in Prostate Cancer Patients Treated With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, E269-E270.	0.8	0
135	EP-1858: Variation of apparent diffusion coefficient in penile bulb after radiotherapy. Radiotherapy and Oncology, 2016, 119, S875-S876.	0.6	0
136	Dose-Effect Quantification of Patient-Reported Urinary Incontinence After Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E225.	0.8	0
137	Prognostic Value of Metabolic Parameters by 18 F-FDG PET/CT in Nasopharyngeal Cancer (NPC) in Non-Endemic Area. International Journal of Radiation Oncology Biology Physics, 2017, 99, S164-S165.	0.8	0
138	Weekly Integral Dose and Use of Lipid Lowering Drugs Are Associated With Worsening of Functional Outcomes in Prostate Cancer Patients Treated With IMRT. International Journal of Radiation Oncology Biology Physics, 2017, 99, S182.	0.8	0
139	Dose-Response Curve for Textural Features of Obturator Muscles as Extracted from T2w-MRI after Prostate Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E719.	0.8	0
140	PO-0729: Normal Tissue Complication Probability for late urinary toxicities after RT for prostate cancer. Radiotherapy and Oncology, 2017, 123, S382-S383.	0.6	0
141	PO-0896: Quantitative MRI-based characterization of obturator muscles after prostate cancer radiotherapy. Radiotherapy and Oncology, 2017, 123, S494-S495.	0.6	0
142	OC-0038: Patterns in ano-rectal dose maps and the risk of late toxicity after prostate radiotherapy. Radiotherapy and Oncology, 2017, 123, S14-S15.	0.6	0
143	Clinical Results for an Active Surveillance Cohort with Localized Prostate Cancer Receiving RT after Exiting Active Surveillance. International Journal of Radiation Oncology Biology Physics, 2018, 102, e145-e146.	0.8	0
144	Evaluation of Inflammatory Marker Levels in Patients Treated with Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e132-e133.	0.8	0

#	Article	IF	Citations
145	OC-0154: REQUITE Big Data Resource for Validating Predictive Models and Biomarkers of Radiotherapy Toxicity. Radiotherapy and Oncology, 2018, 127, S78.	0.6	0
146	PV-0320: NTCP models of late severe urinary symptoms after radical IMRT for prostate cancer. Radiotherapy and Oncology, 2018, 127, S169-S170.	0.6	0
147	SP-0483: The REQUITE project: integrating biomarkers and clinical predictors of radiotherapy side effects. Radiotherapy and Oncology, 2018, 127, S248-S249.	0.6	0
148	PO-0826: Factors affecting self-reported, long-term (1-2 yrs) urinary incontinence from post-prostatectomy RT. Radiotherapy and Oncology, 2018, 127, S431-S432.	0.6	0
149	EP-2009: Metamodelling of late rectal bleeding in patients undergoing radiotherapy for prostate cancer. Radiotherapy and Oncology, 2018, 127, S1095.	0.6	0
150	Active surveillance in prostate cancer patients: Predicting the chance of continuing AS after re-biopsy. European Urology Supplements, 2018, 17, e781-e782.	0.1	0
151	Introducing Information on Saliva Microbiota into Toxicity Modeling: Preliminary Results from a Trial. International Journal of Radiation Oncology Biology Physics, 2019, 105, S223-S224.	0.8	0
152	OC-0615 Predicting urinary toxicity via 2D and 3D dose map analyses in prostate cancer radiotherapy. Radiotherapy and Oncology, 2019, 133, S326.	0.6	0
153	EP-1923 Dimensionality reduction of radiomic features using a clustering coherence-based approach. Radiotherapy and Oncology, 2019, 133, S1046-S1047.	0.6	0
154	EP-1927 Mechanistic modelling of RT damage to microvasculature and of its effect on tumour microenvironment. Radiotherapy and Oncology, 2019, 133, S1048-S1049.	0.6	0
155	OC-0161 Validation of clinical/dosimetric/genetic risk factor models for late RT-induced rectal bleeding. Radiotherapy and Oncology, 2019, 133, S78.	0.6	0
156	PO-0837 Dose-effect relationship for early late incontinence after IMRT in post-prostatectomy patients. Radiotherapy and Oncology, 2019, 133, S439-S440.	0.6	0
157	PO-0850 Comparison of self-reported acute urinary incontinence in pts treated with adjuvant or salvage IMRT. Radiotherapy and Oncology, 2019, 133, S446-S447.	0.6	0
158	PO-0851 Quality of life after whole pelvis RT for prostate cancer: results from a prospective study. Radiotherapy and Oncology, 2019, 133, S447-S448.	0.6	0
159	PO-0859 Validation of genetic variants associated to late severe toxicity after prostate cancer RT. Radiotherapy and Oncology, 2019, 133, S452-S453.	0.6	0
160	EP-1190 Preliminary evaluation of salivary cytokines in patients treated with IMRT for head and neck cancer. Radiotherapy and Oncology, 2019, 133, S659-S660.	0.6	0
161	EP-1280 Identification of gene profiles associated to increased risk of acute toxicity in breast cancer. Radiotherapy and Oncology, 2019, 133, S702.	0.6	0
162	EP-1663 REQUITE multicentre study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 2019, 133, S895.	0.6	0

#	Article	IF	Citations
163	EP-2022 Dose-dependent changes in Tw-MRI texture of obturator muscles after prostate cancer radiotherapy. Radiotherapy and Oncology, 2019, 133, S1108-S1109.	0.6	0
164	Requite Prostate Cohort: Validating Clinical/Dosimetric/Genetic Risk Factors for Late Urinary Toxicity. International Journal of Radiation Oncology Biology Physics, 2019, 105, E317-E318.	0.8	0
165	Development and External Validation of a Predictive Model of Urethra Toxicity for Patients Treated with HDR Brachytherapy Boost Including the Effect of Neo-Adjuvant Androgen Deprivation. International Journal of Radiation Oncology Biology Physics, 2019, 105, S169.	0.8	0
166	Approach Combining Dosimetry and Biology to Predict Severe Toxicity of Radiotherapy for Head and Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology Biology Physics, 2019, 105, S221.	0.8	0
167	OC-0616 Introducing information on gut microbiota into toxicity modeling: preliminary results from a trial. Radiotherapy and Oncology, 2019, 133, S326-S327.	0.6	0
168	Centralized revision of diagnostic pathologic slides for prostate cancer patients on active surveillance: Is it just time- and resource-consuming?. Journal of Clinical Oncology, 2012, 30, 132-132.	1.6	0
169	Modeling fecal incontinence symptoms 6 years after high-dose radiation for prostate cancer: Clinical and dosimetric predictors.. Journal of Clinical Oncology, 2012, 30, 71-71.	1.6	0
170	Modeling acute urinary toxicity after radiotherapy for prostate cancer.. Journal of Clinical Oncology, 2014, 32, 156-156.	1.6	0
171	The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects.. Journal of Clinical Oncology, 2014, 32, 276-276.	1.6	0
172	The REQUITE Project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors.. Journal of Clinical Oncology, 2016, 34, 85-85.	1.6	0
173	Modeling severe late rectal bleeding: Results on a large pooled population of prostate cancer patients.. Journal of Clinical Oncology, 2016, 34, 82-82.	1.6	0
174	Predicting late fecal incontinence risk after RT for prostate cancer: External independent validation.. Journal of Clinical Oncology, 2017, 35, 116-116.	1.6	0
175	Active surveillance in prostate cancer patients: Modeling upgrading and upsizing at 1 year rebiopsy.. Journal of Clinical Oncology, 2018, 36, 90-90.	1.6	0
176	Metamodeling of late rectal bleeding in patients undergoing radiotherapy for prostate cancer.. Journal of Clinical Oncology, 2018, 36, 61-61.	1.6	0
177	Data driven approaches I: conventional statistical inference methods, including linear and logistic regression. , 2018, , 85-127.		0
178	Abstract A032: miR-205 reconstitution sensitizes prostate cancer cells and xenografts to radiotherapy, through PKCÏµ suppression. , 2018, , .		0
179	Predicting Toxicity in External Radiotherapy. , 2019, , 337-363.		0
180	PD-0545: Validation of a predictive model for salivary dysfunction during chemo-IMRT for head-neck cancer. Radiotherapy and Oncology, 2020, 152, S303-S304.	0.6	0

#	Article	IF	Citations
181	PH-0119: Modulations of gut microbiota following radiotherapy for prostate cancer. Radiotherapy and Oncology, 2020, 152, S60-S61.	0.6	0